We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




New AI Algorithms Enable Diagnosis of Difficult Cancers

By LabMedica International staff writers
Posted on 07 Dec 2023

A team of European researchers and companies, led by the Valencia Polytechnic University (UPV, Valencia, Spain), through the CVBLab-HUMAN-tech group, has developed novel artificial intelligence (AI) algorithms to aid the diagnosis and treatment of cancerous tumors that are difficult to interpret clinically. More...

This is one of the main results of the CLARIFY project, which is now in its final months of execution.

CLARIFY is an innovative, multinational, multi-sectorial, and multidisciplinary research initiative with a focus on developing a robust automated digital diagnostic environment based on AI and cloud-oriented data algorithms. The goal is to streamline the interpretation and diagnosis of whole-slide-images (WSIs) globally, to optimize the advantages of digital pathology, and to support pathologists in their routine tasks. The project has concentrated on specific and difficult-to-diagnose cancer types to evaluate the effectiveness of the tools and methods it has developed. These include Triple Negative Breast Cancer (TNBC), High-risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC), and Spitzoid Melanocytic Lesions (SML), representing the diverse challenges present in cancer diagnosis.

Furthermore, the CLARIFY project has yielded additional noteworthy results, such as the creation of comprehensive databases for the studied cancers. These databases are poised to be valuable assets for the medical and scientific communities. The project has also made progress in the secure handling of data in cloud environments, addressing the unique requirements of the healthcare sector. This includes several practical applications within the project's framework, enhancing data security and management.

“In all three cases, the diagnosis is complex and challenging, which we are already addressing with this project,” said Valery Naranjo, project leader. “With these algorithms, we are taking another step forward in facilitating the interpretation of histological images and, ultimately, the diagnosis of these types of cancer for medical professionals.”

Related Links:
Valencia Polytechnic University


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.